Tilray Brands (NASDAQ:TLRY) shares plunged more than 11% following the release of its fiscal second quarter 2025 earnings report, where sales fell short of estimates.
The company reported net revenue of $211 million for the quarter, marking a 9% increase year-over-year but falling short of analysts’ expectations of $216.3 million.
Delta Air Lines Inc (NYSE:DAL) shares surged 9.4% on Friday after the company reported better-than-expected earnings for the fourth quarter of 2024 and issued a strong outlook for 2025.
The airline posted an adjusted earnings per share (EPS) of $1.85, beating estimates by $0.11, while revenue grew 9.4% year-over-year to $15.56 billion, surpassing expectations by $1.08 billion.
Constellation Brands Inc (NYSE:STZ) shares plummeted 13% on Friday morning after the US drinks maker cut its growth outlook for the second time this fiscal year.
The company reported weaker-than-expected Q3 earnings, citing sluggish consumer demand for its beer and wine products.
Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A) saw its shares surge 24% in Friday morning trading after reporting stronger-than-expected first-quarter earnings and maintaining an optimistic full-year forecast.
For Q1 FY25, Walgreens posted adjusted earnings per share (EPS) of $0.51, beating analysts' revised expectations of $0.37.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinuation of GLP-1 agonists, medicines used to manage Type 2 diabetes and obesity.
GLP-1 agonists, such as semaglutide marketed under brand names like Ozempic and Wegovy, are integral in treating metabolic disorders but often lead to side effects including sarcopenia and bone density loss. These adverse effects can force patients to discontinue therapy, undoing its benefits on tissue homeostasis.